Company research / COSM

Cosmos Health Inc. (COSM)

CIK 0001474167 · Nasdaq · Wholesale-Drugs, Proprietaries & Druggists' Sundries

  • Sector Wholesale Trade
  • Incorporated NV
  • Fiscal year ends around Dec 31

For the year ended 2025-12-31, Cosmos Health Inc. reported revenue of $65.27M. Revenue grew 19.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $73.73M.

Key ratios (year ended 2025-12-31)

12.1%
Gross margin
-25.6%
Operating margin
-29.3%
Net margin
-103.9%
Return on year-end equity
19.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-25, first reflected in a filing dated 2023-04-12. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$73.73M$65.27M$54.43M$53.38M$50.35M$56.24M$55.41M$39.68M$37.08M$30.01M$6.76M
Cost of Revenue$66.15M$57.38M$50.12M$49.03M$44.39M$47.91M$47.35M$36.01M$34.68M$28.06M$6.15M
Gross Profit$7.57M$7.90M$4.31M$4.35M$5.96M$8.33M$8.06M$3.66M$2.41M$1.96M$601.0K
R&D Expense$497.6K$519.4K$533.3K$164.9Kn/an/an/an/an/an/an/a
Operating Income-$18.33M-$16.70M-$15.54M-$21.83M-$7.47M-$4.53M$2.71M-$255.8K-$1.23M-$4.87M-$202.5K
Depreciation & Amortization$1.39M$1.37M$1.25M$614.4K$188.9K$449.7K$397.6K$394.6K$43.9Kn/an/a
EBITDA-$16.94M-$15.33M-$14.30M-$21.22M-$7.29M-$4.08M$3.11M$138.8K-$1.18Mn/an/a
Net Income-$24.39M-$19.14M-$16.18M-$18.54M-$13.83M-$7.96M$820.8K-$3.30M-$9.06M-$6.21M-$601.0K
EPS (Diluted)n/a-$0.63-$1.17-$2.15-$33.16-$23.74$0.06-$0.25-$0.68-$0.49$80741.00
Total Assets$61.46M$65.48M$54.31M$66.01M$68.04M$49.43M$43.84M$23.88M$20.69M$10.68M$3.12M
Total Liabilities$40.79M$47.05M$29.78M$29.97M$28.38M$45.05M$48.01M$30.34M$24.01M$13.70M$4.87M
Long-Term Debt$3.19M$3.78M$4.11M$4.61M$5.02M$17.91M$10.77M$0$145.5Kn/an/a
Shareholders' Equity$20.67M$18.42M$24.53M$36.04M$39.28M$4.38M-$4.16M-$6.46M-$3.32M-$3.03M-$1.75M
Cash & Equivalents$1.80M$715.7K$315.1Kn/a$20.75M$286.5K$628.4K$38.5K$864.3K$782.9K$716.6K
Operating Cash Flow-$9.84M-$8.45M-$7.72M-$15.64M-$14.87M-$7.10M-$11.50M-$4.79M-$1.56M-$8.76M-$2.13M
Capital Expenditures$95.6K$55.7K$418.1K$1.31M$74.2K$581.4K$117.7Kn/a$503.4K$55.3K$12.8K
Free Cash Flow-$9.93M-$8.50M-$8.14M-$16.95M-$14.94M-$7.68M-$11.62Mn/a-$2.06M-$8.82M-$2.14M
Share Repurchasesn/an/a$0$100.5Kn/a$376.9K$200.0Kn/an/an/an/a
Shares Outstanding80.67M41.07M23.60M15.90M10.59M686.3K13.07M12.86M13.69M12.67M12.59M
Weighted Average Diluted Sharesn/a30.29M19.15Mn/a1.93M656.9K13.31M13.27M13.31M12.78M125.65M
EPS (Basic)n/a-$0.63-$1.17-$2.15-$33.16-$23.74$0.06-$0.25-$0.68-$0.49$0.00

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView